Analyst Coverage

The following research analysts cover Destiny Pharma.

Mark Brewer, finnCap +44(0)20 7220 0500
Andy Smith, Equity Development +44(0)20 7065 2690
Karl Keegan, Singer Capital Markets +44(0)20 7496 3187
Brian White, Shore Capital +44(0)20 7408 4050

 

Please click on links below to access coverage published:

finnCap finnCap

Analyst research from finnCap can be obtained by registering on the link above

4 April 2023 – Important and supportive new NTCD-M3 data
24 March 2023 – Positive Phase II data with XF-73 published in medical journal
Equity Development Equity Development

20 March 2023 – Onwards and upwards
27 February 2023 – Validation well worth waiting for
Destiny Pharma - Proactive Proactive Investors

For further commentary and interviews, please visit the Destiny Pharma page at Proactive Investors on the link above
Destiny Pharma Vox Markets VOX Markets

For further commentary and interviews, please visit the Destiny Pharma page at Vox Markets on the link above